tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

LYEL Stock Latest News

Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
The FlyDynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
1M ago
A
BB
Lyell Immunopharma price target lowered to $6 from $9 at BofA
PremiumThe Fly
Lyell Immunopharma price target lowered to $6 from $9 at BofA
1M ago
LYEL
Lyell Immunopharma downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Lyell Immunopharma downgraded to Neutral from Buy at H.C. Wainwright
1M ago
LYEL
Lyell Immunopharma’s Promising CAR T-Cell Therapy Trial Results
PremiumCompany Announcements
Lyell Immunopharma’s Promising CAR T-Cell Therapy Trial Results
1M ago
8K
LYEL
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
PremiumPress Releases
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
1M ago
LYEL
Lyell Immunopharma announces initial clinical data from Phase 1 trial of LYL797
PremiumThe FlyLyell Immunopharma announces initial clinical data from Phase 1 trial of LYL797
1M ago
LYEL
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
PremiumPress Releases
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
2M ago
LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
PremiumPress Releases
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
3M ago
LYEL
Lyell Immunopharma reports Q1 revenue $3,000 vs $65,000 last year
PremiumThe Fly
Lyell Immunopharma reports Q1 revenue $3,000 vs $65,000 last year
3M ago
LYEL
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
PremiumPress Releases
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
5M ago
LYEL
Lyell Immunopharma files $400M mixed securities shelf
PremiumThe Fly
Lyell Immunopharma files $400M mixed securities shelf
5M ago
LYEL
Lyell Immunopharma price target lowered to $6 from $8 at H.C. Wainwright
PremiumThe Fly
Lyell Immunopharma price target lowered to $6 from $8 at H.C. Wainwright
5M ago
LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
PremiumPress ReleasesLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
5M ago
LYEL
Lyell Immunopharma Announces Participation in March Investor Conferences
PremiumPress Releases
Lyell Immunopharma Announces Participation in March Investor Conferences
5M ago
LYEL
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
7M ago
LYEL
Lyell Immunopharma announces Orphan Drug Designation for LYL845
PremiumThe Fly
Lyell Immunopharma announces Orphan Drug Designation for LYL845
9M ago
LYEL
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
PremiumPress Releases
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
9M ago
LYEL
Lyell Immunopharma price target lowered to $8 from $9 at H.C. Wainwright
PremiumThe Fly
Lyell Immunopharma price target lowered to $8 from $9 at H.C. Wainwright
9M ago
LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
PremiumPress Releases
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
9M ago
LYEL
Lyell Immunopharma treatment of Stage IIB-IV melanoma granted orphan status
PremiumThe FlyLyell Immunopharma treatment of Stage IIB-IV melanoma granted orphan status
9M ago
LYEL
Lyell Immunopharma is presenting nonclinical data at SITC on LYL119
PremiumThe Fly
Lyell Immunopharma is presenting nonclinical data at SITC on LYL119
9M ago
LYEL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PremiumPress Releases
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10M ago
LYEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >